Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | +300.00% | -99.83% |
03-22 | Cell Source, Inc. announced that it has received $4.76017 million in funding | CI |
2023 | Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 6.596 | 19.34 | 29.13 | 63.92 | 43.22 | 29.96 |
Enterprise Value (EV) 1 | 8.546 | 22.09 | 31.8 | 68.58 | 49.62 | 37.65 |
P/E ratio | -2.18 x | -8.04 x | -5.97 x | -10.7 x | -6.58 x | -4.68 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -3.73 x | -11 x | - | - | - | - |
EV / FCF | -4.53 x | -12.2 x | -39.4 x | -44.2 x | -22.8 x | -28.2 x |
FCF Yield | -22.1% | -8.17% | -2.54% | -2.26% | -4.38% | -3.55% |
Price to Book | -1.5 x | -3.97 x | -5.19 x | -8.19 x | -4.48 x | -2.43 x |
Nbr of stocks (in thousands) | 24,429 | 25,781 | 26,479 | 31,960 | 33,752 | 35,252 |
Reference price 2 | 0.2700 | 0.7500 | 1.100 | 2.000 | 1.280 | 0.8500 |
Announcement Date | 25/07/18 | 01/04/19 | 30/03/20 | 15/04/21 | 15/04/22 | 08/08/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -2.292 | -2.006 | - | - | - | - |
EBIT 1 | -2.293 | -2.006 | -3.805 | -3.638 | -4.019 | -4.175 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.083 | -2.117 | -4.475 | -4.56 | -5.472 | -5.168 |
Net income 1 | -3.083 | -2.117 | -4.475 | -4.56 | -5.472 | -5.168 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.1241 | -0.0932 | -0.1842 | -0.1869 | -0.1946 | -0.1816 |
Free Cash Flow 1 | -1.887 | -1.804 | -0.8061 | -1.552 | -2.176 | -1.336 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 25/07/18 | 01/04/19 | 30/03/20 | 15/04/21 | 15/04/22 | 08/08/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 1.95 | 2.75 | 2.67 | 4.66 | 6.4 | 7.68 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | -0.8507 x | -1.373 x | - | - | - | - |
Free Cash Flow 1 | -1.89 | -1.8 | -0.81 | -1.55 | -2.18 | -1.34 |
ROE (net income / shareholders' equity) | 57.1% | 44.7% | 84% | 66.6% | 61.6% | 46% |
ROA (Net income/ Total Assets) | -386% | -420% | -2,634% | -802% | -656% | -721% |
Assets 1 | 0.7989 | 0.5045 | 0.1699 | 0.5687 | 0.8346 | 0.7165 |
Book Value Per Share 2 | -0.1800 | -0.1900 | -0.2100 | -0.2400 | -0.2900 | -0.3500 |
Cash Flow per Share 2 | 0.0100 | 0 | 0 | 0.0100 | 0 | 0.0100 |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 25/07/18 | 01/04/19 | 30/03/20 | 15/04/21 | 15/04/22 | 08/08/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CLCS Stock
- Financials Cell Source, Inc.